You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Carcinoma, Neuroendocrine

Showing 1 - 25 of 8,789
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Neuroendocrine Carcinomas
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Sep 22, 2023

Pancreatic Adenocarcinoma, Adenosquamous Carcinoma, Pancreatic Neuroendocrine Tumor Trial (ESK981)

Not yet recruiting
  • Pancreatic Adenocarcinoma
  • +6 more
  • (no location specified)
Aug 4, 2023

Neuroendocrine Neoplasms Including Adrenocortical Carcinoma

Recruiting
  • Neuroendocrine Tumors
  • Carcinoma, Neuroendocrine
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    Gastrointestinal Neuroendocrine Carcinoma Trial in Beijing (Durvalumab and Chemotherapy(oxaliplatin and capecitabine))

    Recruiting
    • Gastrointestinal Neuroendocrine Carcinoma
    • Durvalumab and Chemotherapy(oxaliplatin and capecitabine)
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    Oct 1, 2023

    Surufatinib Plus Sintilimab Combined With Chemotherapy in

    Recruiting
    • Gastric Neuroendocrine Carcinoma
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute and Hospital
    Oct 22, 2023

    Large Cell Neuroendocrine Carcinoma of the Lung Trial in Athens (Atezolizumab, Carboplatin, Etoposide)

    Completed
    • Large Cell Neuroendocrine Carcinoma of the Lung
    • Athens, Greece
    • +1 more
    Sep 16, 2023

    Small Cell Lung Cancer, Neuroendocrine Carcinoma Trial in Zhengzhou (ZG006)

    Not yet recruiting
    • Small Cell Lung Cancer
    • Neuroendocrine Carcinoma
    • ZG006
    • Zhengzhou, Henan, China
      Henan Cancer Hospital
    Aug 6, 2023

    Neuroendocrine Carcinoma of the Bladder, Bladder Cancer Trial (Adebrelimab, Etoposide, Cisplatin)

    Not yet recruiting
    • Neuroendocrine Carcinoma of the Bladder
    • Bladder Cancer
    • (no location specified)
    Oct 14, 2023

    Frequency for Patients With Gastric Neuroendocrine Carcinoma

    Completed
    • Gastric Neuroendocrine Carcinoma
      • Fuzhou, Fujian, China
        Chang-ming Huang
      Dec 31, 2022

      Neuroendocrine Carcinoma Trial in Wuhan (Surufatinib and Serplulimab)

      Not yet recruiting
      • Neuroendocrine Carcinoma
      • Surufatinib and Serplulimab
      • Wuhan, Hubei, China
        Cancer Center, Union Hospital, Tongji Medical College, Huazhong
      Feb 18, 2023

      Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/ Phaeochromocytoma, Medullary Thyroid Carcinoma Trial (Lu-177 DOTATATE

      Not yet recruiting
      • Bronchial and Thymic Neuroendocrine Tumour
      • +3 more
      • Lu-177 DOTATATE (Lutathera®)
      • (no location specified)
      Nov 1, 2023

      Epiction of Genomic and Genetic Landscape Identifies CCL5

      Completed
      • Colorectal Neuroendocrine Carcinomas (CRNEC); Genomic Landscape; Genetic Landscape; Prognosis; CCL5; PAX5
        • (no location specified)
        Jan 27, 2023

        Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma Trial in Shanghai (individualized mRNA

        Not yet recruiting
        • Adrenal Cortical Carcinoma
        • +3 more
        • individualized mRNA neoantigen vaccine (mRNA-0523-L001)
        • Shanghai, Shanghai, China
          Ruijin hospital, Shanghai Jiao-Tong University School of Medicin
        Nov 19, 2023

        Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site Trial in San

        Not yet recruiting
        • Neuroendocrine Tumors
        • +2 more
        • San Francisco, California
          University of California, San Francisco
        Feb 17, 2023

        Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma, Pancreatic Carcinoma Trial in Tianjin (Surufatinib, Sintilimab)

        Recruiting
        • Neuroendocrine Tumor Grade 3
        • +2 more
        • Tianjin, Tianjin, China
          Rui Liu
        Nov 17, 2022

        GEP-NET, Neuroendocrine Tumors, Neuroendocrine Carcinoma Trial in Copenhagen (18F-FDG, 64Cu-Dotatate)

        Enrolling by invitation
        • GEP-NET
        • +3 more
        • Copenhagen, Denmark
          Rigshospitalet
        Jan 24, 2023

        High Grade Malignant Neuroendocrine Carcinoma (Diagnosis) Trial in San Francisco, Boston, New York (Pembrolizumab, Irinotecan,

        Completed
        Has Results
        • High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
        • San Francisco, California
        • +2 more
        Dec 5, 2022

        Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Cancer Trial in Tampa (Pembrolizumab, Lenvatinib)

        Active, not recruiting
        • Neuroendocrine Tumors
        • +2 more
        • Tampa, Florida
          H. Lee Moffitt Cancer Center and Research Institute
        Jan 24, 2023

        Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma Trial in Boston

        Not yet recruiting
        • Advanced Prostate Cancer
        • +2 more
        • Boston, Massachusetts
        • +1 more
        Sep 25, 2023

        Small Cell Lung Cancer, Neuroendocrine Carcinoma Trial in Chiba, Tokyo (RO7616789, Tocilizumab)

        Recruiting
        • Small Cell Lung Cancer
        • Neuroendocrine Carcinoma
        • Chiba, Japan
        • +1 more
        Jan 16, 2023

        Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin Trial in Tampa (Lenvatinib Oral

        Recruiting
        • Merkel Cell Carcinoma
        • +2 more
        • Tampa, Florida
          Moffitt Cancer Center
        Dec 30, 2022

        SCLC, Small Cell Cancer, Advanced Solid Tumor Trial run by the NCI (Lurbinectedin, Berzosertib)

        Recruiting
        • SCLC
        • +3 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Jan 20, 2023

        Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC) Trial (PT217)

        Not yet recruiting
        • Small Cell Lung Cancer (SCLC)
        • +3 more
        • (no location specified)
        Dec 7, 2022

        Metastatic Malignant Tumor in the Viscera, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic

        Not yet recruiting
        • Metastatic Malignant Neoplasm in the Viscera
        • +4 more
        • Lutetium Lu 177 Dotatate
        • (no location specified)
        Jan 25, 2023

        Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor of Pancreas Trial in Iowa City, Rochester

        Not yet recruiting
        • Neuroendocrine Tumors
        • +8 more
        • Iowa City, Iowa
        • +1 more
        Nov 23, 2022